Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2022-11-22 Major Shareholding Noti…
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including the purpose of holding (management influence) and specific transaction details. This falls under the category of Major Shareholding Notification.
2022-11-22 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Clinomics' covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 1% confidence The document is a formal regulatory filing from Clinomics regarding the acquisition of shares in another company (NuriBio). It details the acquisition price, purpose, and financial status of the target company. This type of corporate action, involving the acquisition of equity in another entity, is classified as M&A Activity (TAR) within the provided schema.
2022-11-09 Korean
본점소재지변경
Regulatory Filings Classification · 1% confidence The document is a short, formal announcement regarding a change in the company's registered office address (본점소재지변경). It provides the old address, new address, reason for change, and the date of the board resolution. Since this is a standard regulatory disclosure regarding corporate administrative changes that does not fit into specific financial reporting categories like 10-K or IR, and is not a report publication announcement, it falls under the general regulatory filing category.
2022-10-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/KRX). It details the shareholding changes of a specific director (Park Jong-hwa) of Clinomics Co., Ltd. This type of filing is specifically categorized as 'Director's Dealing' (DIRS) as it reports personal share transactions by company executives.
2022-10-06 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the share ownership, changes in holdings (acquisitions), and the purpose of holding (management influence) by major shareholders and special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-10-06 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.